Pentokey Organy (India) Limited Files SEBI Compliance Certificate for Q4FY26

Pentokey Organy (India) Limited has filed its quarterly compliance certificate with BSE Limited, fulfilling regulatory obligations under SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2026.

Regulatory Compliance Filing

The company submitted the mandatory certificate under Regulation 74(5) of SEBI regulations on 15th April, 2026. Company Secretary Saurabh Mishra (M. No. A77775) signed the submission, which included a certificate from the company's registrar and share transfer agent, Datamatics Business Solutions Ltd.

Share Dematerialization Activity

The certificate details share dematerialization and rematerialization activity during the quarter from 01.01.2026 to 31.03.2026:

Depository:	Shares Dematerialized	Shares Rematerialized
National Securities Depository Limited	665	00
Central Depository Services Limited	218	00
Total	883	00

Certificate Confirmation

Datamatics Business Solutions Limited, serving as the registrar and share transfer agent, confirmed that all dematerialized certificates have been properly processed. The registrar verified that:

Physical certificates received for dematerialization have been mutilated and cancelled after due verification
Depository names have been substituted in records as registered owners
All procedures comply with SEBI regulatory requirements

Corporate Details

The filing references Pentokey Organy (India) Limited's scrip code 524210 on BSE Limited. The company maintains its registered office at Unit 509, Western Edge-1, Above Metro Mall, Near Magathane Bus Depot, Borivali East, Mumbai 400066. This quarterly submission ensures continued compliance with securities market regulations and maintains transparency in share transfer operations.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+12.92%	+18.12%	+19.37%	-16.72%	-14.68%	+211.79%

Pentokey Organy (India) Limited has scheduled a board meeting for January 21, 2026, to review and approve its unaudited financial results for the third quarter of fiscal year 2026. The pharmaceutical company made this announcement through a formal communication to BSE Limited on January 16, 2026.

Board Meeting Details

The meeting specifics are outlined in the following table:

Parameter:	Details
Meeting Date:	Wednesday, January 21, 2026
Purpose:	Consider and approve unaudited financial results
Quarter Period:	Ended December 31, 2025 (Q3FY26)
BSE Scrip Code:	524210
Regulation:	SEBI Listing Obligations and Disclosure Requirements Regulations, 2015

Trading Window Status

The company has provided important information regarding its trading window restrictions. Currently, the trading window for dealing in Pentokey Organy securities remains closed in accordance with SEBI's Prohibition of Insider Trading Regulations, 2015, and the company's internal Code of Conduct for Prevention of Insider Trading.

The trading window will reopen 48 hours after the financial results for the quarter ended December 31, 2025, become generally available to the public. This standard practice ensures compliance with insider trading regulations and maintains market integrity.

Regulatory Compliance

The announcement was made pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary Saurabh Mishra signed the official communication, which was digitally authenticated on January 16, 2026.

The company has also uploaded this intimation on its official website at www.pentokey.com , ensuring transparent communication with all stakeholders. This formal notification allows investors and market participants to prepare for the upcoming financial disclosure and plan their investment decisions accordingly.